GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Book Value per Share

Rakovina Therapeutics (TSXV:RKV) Book Value per Share : C$0.05 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Book Value per Share?

Rakovina Therapeutics's book value per share for the quarter that ended in Dec. 2024 was C$0.05.

During the past 12 months, Rakovina Therapeutics's average Book Value Per Share Growth Rate was -7.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -26.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Rakovina Therapeutics was -26.70% per year. The lowest was -26.70% per year. And the median was -26.70% per year.

Rakovina Therapeutics's current price is C$0.06. Its book value per share for the quarter that ended in Dec. 2024 was C$0.05. Hence, today's PB Ratio of Rakovina Therapeutics is 1.25.

During the past 4 years, the highest P/B Ratio of Rakovina Therapeutics was 1.25. The lowest was 0.00. And the median was 0.00.


Rakovina Therapeutics Book Value per Share Historical Data

The historical data trend for Rakovina Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Book Value per Share Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Book Value per Share
0.12 0.09 0.05 0.05

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.05 0.03 0.05

Competitive Comparison of Rakovina Therapeutics's Book Value per Share

For the Biotechnology subindustry, Rakovina Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's PB Ratio falls into.


;
;

Rakovina Therapeutics Book Value per Share Calculation

Rakovina Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.30-0.00)/90.29
=0.05

Rakovina Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.30-0.00)/90.29
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Rakovina Therapeutics  (TSXV:RKV) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Rakovina Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.
Executives
Jeffrey Bacha Senior Officer
Alfredo De Lucrezia Director, Senior Officer
Michael Liggett Director
Mads Daugaard Senior Officer
David Hyman Senior Officer
John Michael Langlands Senior Officer

Rakovina Therapeutics Headlines

No Headlines